Inhibition of proliferation by Laminin

层粘连蛋白抑制增殖

• 批准号: 8691542
• 负责人: Vito Quaranta
• 金额: $ 20.46万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-10 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8691542
• 关键词: Accounting; Adhesions; Antibodies; Basement membrane; Biological Assay; Breast; Cell Adhesion; Cell Line; Cell Survival; Cells; Cessation of life; Clinical; Collagen; Colorectal; Complex; Data; Dependence; Development; Energy Metabolism; Energy Metabolism Pathway; Enzymes; Epithelial; Epithelial Cells; Exposure to; Extracellular Matrix; Fibronectins; Focal Adhesion Kinase 1; Future; Gene Expression; Genes; Genetic Transcription; Growth; Growth Factor Receptors; Human; Integrins; Kidney; Knock-out; Knowledge; Laboratories; Laminin; Ligands; Malignant Epithelial Cell; Malignant Neoplasms; Measures; Mediating; Metabolic; Metabolic Pathway; Metabolic stress; Metabolism; Molecular; NADP; Nude Mice; Oncogenes; Oxidative Phosphorylation; Phenocopy; Phosphorylation; Process; Production; Property; Prostate; Regulation; Reporting; Role; SLC2A1 gene; Secondary to; Signal Pathway; Signal Transduction; Signaling Protein; Surface; Testing; Warburg Effect; Xenograft procedure; aerobic glycolysis; anticancer research; base; cancer cell; cancer therapy; cancer type; capsule; cell type; glucose uptake; macromolecule; novel; prevent; public health relevance; receptor; treatment strategy; tumor; tumor growth; tumor microenvironment; tumor progression; tumor xenograft

DESCRIPTION (provided by applicant): Extracellular matrix (ECM) macromolecules are major components of the tumor microenvironment and are involved in cancer progression-related processes including integrin mediated permissive proliferative co-signals. Unexpectedly, preliminary data in our laboratory indicate that the basement membrane ECM macromolecule, Laminin-332 (Ln-332), has an anti-proliferative effect on cancer cells. On further examination, growth inhibition by Ln-332 appears to be secondary to an integrin mediated process that shifts cancer cells out of Warburg-like- metabolism, itself required for fast proliferation. Thus, the carcinoma cell line 804G which secretes its own Ln-332 substrate, forms small tumors in kidney capsule xenografts. Knockdown (804G-kd) of either of two Ln-332 subunits leads to greatly decreased Ln-332 secretion. Injected in the subrenal capsule of athymic mice, 804G-kd cells form tumors >50 fold larger than 804G parental, in which markers of both increased proliferation (Ki-67) and glucose uptake (GLUT-1 surface expression) are detectable. To account for this drastic proliferative increase, we compared metabolic parameters. In 804G-kd we detected a shift toward aerobic glycolysis (Warburg---like metabolism) characterized by increased GLUT1 surface expression, increased NADPH/NADP ratio, increased glucose uptake and lactate production, all aerobic glycolysis landmarks. The aerobic glycolysis shift is reversed if 804G-kd cells are plated on exogenous Ln-332 substrates. Moreover, the shift is phenocopied in 804G cells by antibody-based inhibition of ¿1but not by knockdown of ¿4 integrin, suggesting that, of the two Ln-332 integrin receptors, ¿3¿1 but not ¿6¿4mediates Ln-332 metabolic effects. Taken together, these data support the concept that Ln-332 negatively regulates proliferation by metabolic reprogramming that prevents aerobic glycolysis. In this application, we focus on investigating molecular mechanisms that connect ECM-initiated signaling with metabolic enzyme networks, hoping to break new ground for new directions in cancer research. In Aim 1, we will test the hypothesis that ¿1 integrins negatively regulate proliferation by inhibiting Warburg-like metabolism. In Aim 2, we will identify the molecular mechanism by which integrin ¿3¿1 downstream signaling negatively regulates aerobic glycolysis. If successful, this project will deepen existing knowledge of tumor growth regulation by the microenvironment, with the potential to create exciting opportunities for currently unforeseen cancer treatment strategies.

描述(申请人提供)：细胞外基质(ECM)大分子是肿瘤微环境的主要成分，参与癌症进展相关的过程，包括整合素介导的允许性增殖共信号。出乎意料的是，我们实验室的初步数据表明，基底膜ECM大分子层粘连蛋白-332(Ln-332)对癌细胞具有抗增殖作用。在进一步的检查中，Ln-332的生长抑制似乎次于整合素介导的过程，该过程使癌细胞脱离华宝样代谢，而华宝样代谢本身是快速增殖所必需的。因此，癌细胞804G分泌自己的Ln-332底物，在肾被膜异种移植瘤中形成小肿瘤。两个Ln-332亚基中的任何一个被敲除(804G-kd)会导致Ln-332分泌显著减少。将804G-kd细胞注射到无瘤小鼠的肾被膜下，形成的肿瘤比804G亲本细胞大50倍，在这些肿瘤中可以检测到增殖增加(Ki-67)和葡萄糖摄取(GLUT-1表面表达)的标志。为了解释这种急剧的增殖性增加，我们比较了代谢参数。在804G-kd中，我们检测到了向有氧糖酵解(Warburg-代谢)的转变，其特征是GLUT1表面表达增加，NADPH/NADP比率增加，葡萄糖摄取和乳酸产生增加，所有这些都是有氧糖酵解的标志。如果804G-kd细胞被接种在外源Ln-332底物上，则有氧糖酵解位移被逆转。此外，在804G细胞中，这种转变是通过基于抗体的抑制而不是通过敲除整合素来实现的，这表明，在两个Ln-332整合素受体中，3 1而不是6介导了Ln-332的代谢作用。综上所述，这些数据支持这样的概念，即Ln-332通过阻止有氧糖酵解的代谢重新编程来负向调节增殖。在这一应用中，我们专注于研究连接ECM启动的信号与代谢酶网络的分子机制，希望为癌症研究的新方向开辟新的天地。在目标1中，我们将检验这一假设，即整合素通过抑制Warburg样代谢来负向调节增殖。在目标2中，我们将确定整合素3下游信号负性调节有氧糖酵解的分子机制。如果成功，这个项目将加深现有的微环境对肿瘤生长调控的知识，有可能为目前无法预见的癌症治疗策略创造令人兴奋的机会。